Interactive Session:
20. Therapeutic Approach for GNR: The Clinical Evidence, a Case-Based Symposium
Thursday, October 27, 2016: 8:30 AM-10:00 AM
Room: Theater A & B

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • Describe the clinical evidence available for the treatment of KPC-containing Enterobacteriaceae using specific cases as example.
  • Outline the clinical impact and therapeutic differences between different mechanisms causing carbapenem resistance
  • Review the treatment options for infections caused by GNR carrying metallo-B-lactamases in a real situation.
  • Discuss the therapeutic approach for colistin-resistant microorganisms

Target Audience: Academicians, Epidemiologists, Fellows, Healthcare workers, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Members-in-training, Microbiologists, Nurses, Pharmacists, Public health practitioners, Researchers, Scientists

Tracks: Investigative ID, Global ID, Epidemiology and Infection Control, Adult ID

Interactive Moderators:  Cesar Arias, MD, PhD, FIDSA, University of Texas McGovern Medical School at Houston and Robert A. Bonomo, MD, Case Western Reserve University

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours 0.15 of pharmacy CE

ACPE Number: 0221-9999-16-216-L01-P

Disclosures:

C. Arias, Forest/Actavis: Grant Investigator and Speaker's Bureau , Research support
Theravance: Consultant , Grant Investigator and Speaker's Bureau , Grant recipient and Speaker honorarium
Pfizer: Grant Investigator , Scientific Advisor and Speaker's Bureau , Grant recipient and Speaker honorarium
Cubist: Consultant , Grant Investigator and Scientific Advisor , Consulting fee , Grant recipient and Speaker honorarium
Bayer: Consultant and Scientific Advisor , Consulting fee
Merck: Grant Investigator and Speaker's Bureau , Research grant and Speaker honorarium
Astra-Zeneca: Speaker's Bureau , Speaker honorarium
Novartis: Speaker's Bureau , Speaker honorarium
The Medicines Company: Speaker's Bureau , Speaker honorarium

R. A. Bonomo, Merck: Grant Investigator , Research grant
Wockhardt: Grant Investigator , Grant recipient
Allergan: Grant Investigator , Research grant

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.